Why the study?
What is the safety profile of ziprasidone, particularly regarding QTc prolongation and mortality?
Design
Review
Authors
Loading...
Supports ziprasidone use despite QTc effects; leaves open need for prospective arrhythmia outcome trials.
What is the safety profile of ziprasidone, particularly regarding QTc prolongation and mortality?
Despite causing QTc prolongation, ziprasidone appears to have a favorable safety profile without an increased risk of torsade de pointes or sudden death.
Paul J. Goodnick (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: